Researchers recently investigated the value of External Comparator Cohort (ECC) studies using Real-World Data in Oncology. These studies offer a more reliable way to estimate treatment differences than traditional single-arm trials (SAT). Specifically, the researchers evaluated how healthcare professionals and regulators perceive evidence when establishing overall survival (OS) benefits in advanced cancers.

Optimizing Real-World Data in Oncology for Better Evidence

The results showed that high-quality ECC studies significantly outperform SATs in perceived strength of evidence. For instance, an ECC study demonstrating a 3-month OS improvement had nearly 15 times higher odds of receiving a higher evidence rating than an SAT. However, randomized controlled trials (RCTs) still remain the gold standard, with odds ratios for evidence strength exceeding 300. Notably, healthcare professionals from organizations like ESMO and EHA view real-world evidence much more favorably than regulatory assessors do.

Furthermore, the quality of the data source plays a critical role in these assessments. High-quality RWD allows for better handling of selection bias and data heterogeneity. Consequently, these designs are becoming essential when ethical or practical constraints prevent traditional randomization. Clinicians must weigh the observed survival benefit against the risk of symptomatic toxicity when interpreting these findings.

How does an External Comparator Cohort (ECC) differ from a Single-Arm Trial (SAT)?

An SAT evaluates a drug without a control group, making it difficult to determine the true treatment effect. In contrast, an ECC uses real-world data from patients treated with standard care to provide a comparative context for the experimental therapy.

Why do regulators and clinicians view Real-World Data (RWD) differently?

Clinicians often value the practical insights and representative populations found in RWD. Regulatory agencies, however, remain more cautious due to potential selection bias and the lack of prospective randomization inherent in non-randomized designs.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Pignatti F et al. Assessing Overall Survival Benefits in Advanced Cancers: The Role of External Comparator Cohort Studies with Real-World Data. Clin Pharmacol Ther. 2026 Feb 11. doi: 10.1002/cpt.70213. PMID: 41669939.


2. Yap TA et al. Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development. Front Oncol. 2021;11:695936.


3. Rippin G et al. A Review of Causal Inference for External Comparator Arm Studies. Drug Saf. 2022;45(8):815-837.